These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1008 related items for PubMed ID: 28295308

  • 1. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
    Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J.
    Int J Cancer; 2017 Jun 15; 140(12):2805-2819. PubMed ID: 28295308
    [Abstract] [Full Text] [Related]

  • 2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J, Boland A, Bates V, Vecchio F, Dundar Y, Chaplin M, Green JA.
    Cochrane Database Syst Rev; 2021 Mar 18; 3(3):CD010383. PubMed ID: 33734432
    [Abstract] [Full Text] [Related]

  • 3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.
    Cochrane Database Syst Rev; 2016 May 25; (5):CD010383. PubMed ID: 27223332
    [Abstract] [Full Text] [Related]

  • 4. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
    Ding PN, Lord SJ, Gebski V, Links M, Bray V, Gralla RJ, Yang JC, Lee CK.
    J Thorac Oncol; 2017 Apr 25; 12(4):633-643. PubMed ID: 28007626
    [Abstract] [Full Text] [Related]

  • 5. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M, Okamoto I, Nakagawa K.
    Lung Cancer; 2015 Apr 25; 88(1):74-9. PubMed ID: 25704957
    [Abstract] [Full Text] [Related]

  • 6. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.
    Popat S, Mok T, Yang JC, Wu YL, Lungershausen J, Stammberger U, Griebsch I, Fonseca T, Paz-Ares L.
    Lung Cancer; 2014 Aug 25; 85(2):230-8. PubMed ID: 24929780
    [Abstract] [Full Text] [Related]

  • 7. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
    Burotto M, Manasanch EE, Wilkerson J, Fojo T.
    Oncologist; 2015 Apr 25; 20(4):400-10. PubMed ID: 25795635
    [Abstract] [Full Text] [Related]

  • 8. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Hockenhull J, Proudlove C, Dundar Y, Richardson M, Dickson R, Mullard A, Marshall E.
    Health Technol Assess; 2015 Jun 25; 19(47):1-134. PubMed ID: 26134145
    [Abstract] [Full Text] [Related]

  • 9. Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.
    Haspinger ER, Agustoni F, Torri V, Gelsomino F, Platania M, Zilembo N, Gallucci R, Garassino MC, Cinquini M.
    Crit Rev Oncol Hematol; 2015 May 25; 94(2):213-27. PubMed ID: 25523487
    [Abstract] [Full Text] [Related]

  • 10. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
    Horn L, Gettinger S, Camidge DR, Smit EF, Janjigian YY, Miller VA, Pao W, Freiwald M, Fan J, Wang B, Chand VK, Groen HJM.
    Lung Cancer; 2017 Nov 25; 113():51-58. PubMed ID: 29110849
    [Abstract] [Full Text] [Related]

  • 11. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    Liang W, Wu X, Fang W, Zhao Y, Yang Y, Hu Z, Xue C, Zhang J, Zhang J, Ma Y, Zhou T, Yan Y, Hou X, Qin T, Dinglin X, Tian Y, Huang P, Huang Y, Zhao H, Zhang L.
    PLoS One; 2014 Nov 25; 9(2):e85245. PubMed ID: 24533047
    [Abstract] [Full Text] [Related]

  • 12. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS, Kwon JW, Shin S, Kim HS, Kim H.
    J Clin Pharm Ther; 2015 Dec 25; 40(6):661-71. PubMed ID: 26573867
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
    Zhang Y, Zhang Z, Huang X, Kang S, Chen G, Wu M, Miao S, Huang Y, Zhao H, Zhang L.
    Clin Lung Cancer; 2017 Sep 25; 18(5):e333-e340. PubMed ID: 28462807
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.
    Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM.
    Cancer Res Treat; 2019 Apr 25; 51(2):502-509. PubMed ID: 29898592
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study.
    Hung LJ, Hsu PC, Yang CT, Kuo CS, Chang JW, Huang CY, Chang CF, Wu CE.
    Aging (Albany NY); 2024 Jan 08; 16(1):550-567. PubMed ID: 38194721
    [Abstract] [Full Text] [Related]

  • 16. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K, Hata A, Takeshita J, Okuda C, Kaji R, Masago K, Fujita S, Katakami N.
    Cancer Chemother Pharmacol; 2015 Oct 08; 76(4):835-41. PubMed ID: 26349474
    [Abstract] [Full Text] [Related]

  • 17. Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations.
    Haaland B, Tan PS, de Castro G, Lopes G.
    J Thorac Oncol; 2014 Jun 08; 9(6):805-11. PubMed ID: 24787964
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
    Lee VH, Leung DK, Choy TS, Lam KO, Lam PM, Leung TW, Kwong DL.
    BMC Cancer; 2016 Feb 24; 16():147. PubMed ID: 26911310
    [Abstract] [Full Text] [Related]

  • 19. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J, Tien Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L.
    Value Health; 2015 Sep 24; 18(6):774-82. PubMed ID: 26409604
    [Abstract] [Full Text] [Related]

  • 20. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
    Brückl W, Tufman A, Huber RM.
    Expert Rev Anticancer Ther; 2017 Feb 24; 17(2):143-155. PubMed ID: 27898252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.